Wang Yongxiang graduated from China University of Science and Technology with a bachelor's degree in biophysics, continued his study in Japan and in the United States, and became Ph.D. in biotechnology from his studies at Helsinki University of Technology, Finland. Dr. Wang is an international expert in standardized production management (cGMP) of aseptic pharmaceutical preparations. Currently, Dr. Wang is the Vice President of Production and Compliance Affairs of Sirnaomics and Chief Technology Officer of Greater China. Dr. Wang is responsible for the quality compliance of the Company's clinical drug production and guiding the engineering construction of the polypeptide nucleic acid nano drug innovation base of Sirnaomics Biomedical Technology (Guangzhou) Co., Ltd.

Dr. Wang has long been committed to the exchange of biomedical science and technology between China and the United States and has years of practical experience. Focusing on the technical operation in the fields of bioengineering, biomedical research, and development as well as industrialization, and the promotion of industrialized international standards. Dr.Wang has published more than 50 peer-reviewed research papers and has many international patents related to the development of biotechnology projects.

Wang served as the first vice president of technical operation of Wuxi Biopharmaceutical Factory of Yaoming Kant Company. Wang also assisted in the establishment of the Company's biopharmaceutical production base. Dr. Wang established and improved its GMP operation mechanism and quality system and also produced the first listed outsourced biopharmaceutical.Wang participated in the US National Special Project to Combat Ebola Virus Epidemic in West Africa, participated in the WHO Global Ebola Vaccine Production Coordination, and served as the Quality Director of the Expert Group. During the period,Wang participated in the emergency response of Ebola Epidemicandcontinued the completion of all the quality management and industrial production-related work of the anti-Ebola virus vaccine (rVSV-ZEBOV-GP) in the technology transfer of Merk Sharp & Dohme Corp.